MONTREAL, April 26th, 2021 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of an invited review article by its CSO, Dr. Andrew Vaillant entitled “Transaminase Elevations during Treatment of Chronic Hepatitis B infection: Safety Considerations and Role in Achieving Functional Cure” in a special issue in the journal Viruses on “Recent Advances in Management of Hepatitis B and towards Achieving a HBV Cure” here.
This review includes an update on the following:
- The localization and extent of HBV infection (and HBV DNA integration) in the liver during the
natural history of HBV infection.
- The impact of HBV infection on hepatocyte function.
- The tissue sources and underlying mechanisms of ALT AST and GGT isozyme elevations in the
blood during the natural history and therapy of chronic HBV infection.
- Modelling how the interplay between liver regeneration and depletion of the functional liver
reservoir impacts the safety of transaminase flares during the therapy of chronic HBV infection,
including in cirrhotic subjects.
- Examining the correlation between host mediated transaminase flares during therapy and
improved virologic and hepatic status and increased rates of functional cure in cirrhotic and noncirrhotic subjects.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical
data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the
development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further
information about Replicor please visit our website at www.replicor.com.